2,608
Views
25
CrossRef citations to date
0
Altmetric
Research Article

PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer

, , , , , , , , , , , & show all
Pages 1746-1755 | Received 22 May 2018, Accepted 06 Aug 2018, Published online: 03 Nov 2018

References

  • Agemy L, Friedmann-Morvinski D, Kotamraju VR, et al. (2011). Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci Usa USA 108:17450–5.
  • Ansell SM, Lesokhin AM, Borrello I, et al. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311–19.
  • Antonia SJ, López-Martin JA, Bendell J, et al. (2016). Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883–95.
  • Armand P, Shipp MA, Ribrag V, et al. (2016). Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34:3733–9.
  • Chang HN, Liu BY, Qi YK, et al. (2015). Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew Chem Int Ed Engl 54:11760–4.
  • Chen R, Zinzani PL, Fanale MA, et al. (2017). Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma. J Clin Oncol 35:2125–32.
  • Dömling A, Holak TA. (2014). Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed Engl 53:2286–8.
  • Dudley ME, Wunderlich J, Nishimura MI, et al. (2001). Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363–73.
  • Fesnak AD, June CH, Levine BL. (2016). Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16:566–81.
  • Hájek R, Vorlicek J, Slavik M. (1996). Paclitaxel (Taxol): a review of its antitumor activity in clinical studies minireview. Neoplasma 43:141–54.
  • Hoffman JA, Giraudo E, Singh M, et al. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4:383–91.
  • Huang S, Yu X, Yang L, et al. (2014). The efficacy of nimodipine drug delivery using mPEG-PLA micelles and mPEG-PLA/TPGS mixed micelles. Eur J Pharm Sci 63:187–98.
  • Järvinen TA, Ruoslahti E. (2007). Molecular changes in the vasculature of injured tissues. Am J Pathol 171:702–11.
  • Lavolé A, Guihot A, Veyri M, et al. (2018). PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy? Ann Oncol 29:1065–6.
  • Li X, Lian Z, Wang S, et al. (2018). Interactions between EGFR and PD-1/PD-L1 pathway: implications for treatment of NSCLC. Cancer Lett 418:1–9.
  • Mackensen A, Meidenbauer N, Vogl S, et al. (2006). Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060–9.
  • Nayak L, Iwamoto FM, LaCasce A, et al. (2017). PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129:3071–3.
  • Prodeus A, Abdul-Wahid A, Fischer NW, et al. (2015). Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers. Mol Ther Nucleic Acids 4:e237.
  • Ravi R, Noonan KA, Pham V, et al. (2018). Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nat Commun 9:741.
  • Ruan S, Xiao W, Hu C, et al. (2017). Ligand-mediated and enzyme-directed precise targeting and retention for the enhanced treatment of glioblastoma. ACS Appl Mater Interfaces 9:20348–60.
  • Song X, Shao Y, Jiang T, et al. (2018). Radiotherapy upregulates programmed death ligand-1 through the pathways downstream of epidermal growth factor receptor in glioma. EBioMedicine 28:105–13.
  • Vari F, Arpon D, Keane C, et al. (2018). Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131:1809–19.
  • Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. (2010). Synthetic therapeutic peptides: science and market. Drug Discov Today 15:40–56.
  • Xia H, Gao X, Gu G, et al. (2011). Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 32:9888–98.
  • Yee C, Thompson JA, Byrd D, et al. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci Usa USA 99:16168–73.
  • Zhan C, Gu B, Xie C, et al. (2010). Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 143:136–42.
  • Zhao S, Dai W, He B, et al. (2012). Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J Control Release 158:413–23.